Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Net Cash Flow: 2014-2024

Historic Net Cash Flow for Theravance Biopharma (TBPH) over the last 11 years, with Dec 2024 value amounting to -$1.7 million.

  • Theravance Biopharma's Net Cash Flow fell 366.56% to -$107.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $151.4 million, marking a year-over-year increase of 413.40%. This contributed to the annual value of -$1.7 million for FY2024, which is 99.32% up from last year.
  • Per Theravance Biopharma's latest filing, its Net Cash Flow stood at -$1.7 million for FY2024, which was up 99.32% from -$258.6 million recorded in FY2023.
  • In the past 5 years, Theravance Biopharma's Net Cash Flow registered a high of $208.2 million during FY2022, and its lowest value of -$258.6 million during FY2023.
  • Over the past 3 years, Theravance Biopharma's median Net Cash Flow value was -$1.7 million (recorded in 2024), while the average stood at -$17.4 million.
  • Per our database at Business Quant, Theravance Biopharma's Net Cash Flow skyrocketed by 1,172.10% in 2022 and then plummeted by 224.21% in 2023.
  • Yearly analysis of 5 years shows Theravance Biopharma's Net Cash Flow stood at $27.9 million in 2020, then crashed by 169.72% to -$19.4 million in 2021, then surged by 1,172.10% to $208.2 million in 2022, then plummeted by 224.21% to -$258.6 million in 2023, then skyrocketed by 99.32% to -$1.7 million in 2024.